Authors
Latest:
Improving Oncology Clinical Trial AccrualWe spoke with Dr. Mikkael Sekeres on the difficulty of cancer patients meeting eligibility criteria for clinical trials.
Latest:
Epidermal Growth Factor Receptor Inhibitor Cutaneous Side EffectsThis slide show highlights some of the cutaneous side effects related to the use of epidermal growth factor receptor inhibitors (EGFRI).
Latest:
A 75-Year-Old Male Develops Painful Erythema Around His Nails After Starting TreatmentA 75-year-old male patient develops painful erythema around his nails 10 weeks after starting cancer treatment. Which medication is most likely responsible?
Latest:
A Multidisciplinary Approach to Treating Immune-Related Adverse EventsWe spoke with Monica Fradkin on ways to help minimize adverse events in patients receiving immunotherapy treatment at the Oncology Nursing Society 42nd Annual Congress, held May 4–7 in Denver.
Latest:
The Personal Side of PalbociclibJust when you think you've run out of treatment options for a patient, new drugs are approved and quickly available. In the past year, there have been dozens of new drugs for all types of solid and blood malignancies. One of the most recent was just approved this year for breast cancer.
Latest:
Studying the Efficacy of Durvalumab and Radiation Therapy in Bladder CancerWe spoke with Dr. Monika Joshi on the use of radiation therapy and durvalumab in patients with locally advanced bladder cancer.
Latest:
Next-Generation Sequencing for SarcomaWe spoke with Mrinal M. Gounder, MD, about next-generation sequencing for sarcoma, and how it can be used to inform treatment decisions and prognosis.
Latest:
Nicholas J. Short, MD, on the Future of ALL and Possibilities for Transplant in These PatientsShort expanded on the future of acute lymphoblastic leukemia and transplantation necessity at the 2020 ASH Annual Meeting & Exposition.
Latest:
March 2016 News RecapIn case you missed it, check out our March recap featuring some of the latest in clinical trial news, a new indication for Afinitor, how genetics affect prognosis, and more.
Latest:
Novel Nanomedicine Development for GlioblastomaWe spoke with Dr. Priya Kumthekar and Dr. Alexander Stegh about their nucleic acid-based therapeutic development that targets glioblastoma.
Latest:
CDK 4/6 Inhibitors for Breast CancerIn this interview, we are discussing the impact that CDK 4/6 inhibitors are having on specific types of breast cancer.
Latest:
Analyzing Various Molecular Subtypes in Bladder CancerDr. Roland Seiler presented an analysis of how different bladder cancer molecular subtypes respond to neoadjuvant chemotherapy at the 2017 ASCO Genitourinary Cancer Symposium.
Latest:
Is There a Role for Intralesional Therapy in Melanoma?On Monday during ASCO, Dr. Axel Hauschild reviewed the role of intralesional therapy in melanoma in a sub-session of the melanoma abstract review talk entitled “Evolving Utility of Intralesional Therapy for Melanoma.”
Latest:
Patient Ethnicity Differences in Epstein-Barr Virus and DLBCL OutcomesAs part of OncoTherapy Network’s coverage of the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH), held December 3–6 in San Diego, California, we spoke with Sean Tracy, MD, PhD, at the Mayo Clinic in Rochester, Minnesota.
Latest:
Epidermal Growth Factor Receptor Inhibitor Cutaneous Side EffectsThis slide show highlights some of the cutaneous side effects related to the use of epidermal growth factor receptor inhibitors (EGFRI).
Latest:
Oncology Peer Review On-The-Go: Focus of Current and Emerging Therapies in Follicular LymphomaKirk E. Cahill, MD, and Sonali M. Smith, MD, spoke with CancerNetwork® about their review of the current management and treatment of follicular lymphoma published in the journal ONCOLOGY®.
Latest:
Combining Immune & Targeted Therapies in Melanoma: A Paradigm for Other Tumor Types?The story of how the targeted therapies, immunotherapies, and combinations of these therapies have been developed for use in patients with advanced melanoma holds a number of important lessons for the development of agents for use in other tumor types.
Latest:
ASCO 2016: Phase I Trial Results With Vorinostat in Head and Neck CancerIn this interview, Theodoros Teknos, MD, discusses the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.
Latest:
Identifying and Treating Cytokine Release SyndromeWe spoke with Victoria Miller, FNP-BC, on how to identify and treat cytokine release syndrome in cancer patients being treated with immunotherapy at the Oncology Nursing Society 42nd Annual Congress, held May 4–7 in Denver.
Latest:
Venetoclax in the Context of the Current CLL Treatment ParadigmIn this podcast interview, Dr. William Wierda discusses the role of venetoclax in treating patients with chronic lymphocytic leukemia, particularly in light of recent trial results.
